Alexza Pharmaceuticals Inc (ALXA)

0.94
0.01 1.63
Prev Close 0.92
Open 0.92
Day Low/High 0.91 / 0.95
52 Wk Low/High 0.22 / 1.60
Volume 305.73K
Avg Volume 144.20K
Exchange
Shares Outstanding 21.75M
Market Cap 20.01M
EPS -1.10
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Exelixis, Protalix, Arena

Biotech Stock Mailbag: Exelixis, Protalix, Arena

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

29 Drugs Facing FDA Approval in 2012

29 Drugs Facing FDA Approval in 2012

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.

The Next Big Thing in Biotech: Alexza

The Next Big Thing in Biotech: Alexza

Adam Feuerstein, senior columnist for TheStreet, explains why Alexza Pharmaceuticals is the next big thing in biotech.

Alexza Pharmaceuticals Inc. Stock Downgraded (ALXA)

Alexza Pharmaceuticals Inc. Stock Downgraded (ALXA)

Alexza Pharmaceuticals (Nasdaq:ALXA) has been downgraded by TheStreet Ratings from from a hold to sell.

Alexza Stock Gaps Down On Today's Open (ALXA)

Alexza Stock Gaps Down On Today's Open (ALXA)

Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) were gapping down Friday morning with an open price 31.4% lower than Thursday's closing price. The stock closed at 70 cents yesterday and opened today's trading at 48 cents.

5 Stocks Insiders Are Loading Up On

5 Stocks Insiders Are Loading Up On

Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

Alexza Stock Gaps Up On Today's Open (ALXA)

Alexza Stock Gaps Up On Today's Open (ALXA)

Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) were gapping up Tuesday morning with an open price 14.5% higher than Friday's closing price. The stock closed at 83 cents yesterday and opened today's trading at 95 cents.

Biotech Stock Live Chat: 2012 Preview

Biotech Stock Live Chat: 2012 Preview

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Alexza Stock Soars (ALXA)

Alexza Stock Soars (ALXA)

Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) have taken a tremendous swing upward. The stock is trading at 89 cents as of 10:10 a.m. ET, 42.5% above Monday's closing price of 62 cents. Volume is at 6.7 million, 11.9 times the daily average of 565,100.

Alexza Pharma: FDA Panel Live Blog

Alexza Pharma: FDA Panel Live Blog

An FDA panel is reviewing Alexza's Adasuve, which is seeking approval for treatment of agitation in schizophrenia patients.

Alexza Stock Soars (ALXA)

Alexza Stock Soars (ALXA)

Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) have taken a tremendous swing upward. The stock is trading at 63 cents as of 1:20 p.m. ET, 21.1% above Thursday's closing price of 52 cents. Volume is at 2.2 million, 5.6 times the daily average of 402,600.

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

Alexza Pharmaceuticals Inc. Stock Upgraded (ALXA)

Alexza Pharmaceuticals Inc. Stock Upgraded (ALXA)

Alexza Pharmaceuticals (Nasdaq:ALXA) has been upgraded by TheStreet Ratings from a sell to hold.

Biotech Calendar: 2011-12 FDA Drug Approvals

Biotech Calendar: 2011-12 FDA Drug Approvals

An updated list of drug and biotech firms with drug approvals expected through the first quarter 2012.

Biotech Calendar: Key Dates for August

Biotech Calendar: Key Dates for August

Here's a list of August's potentially stock-moving biotech events.

Biotech Stock Mailbag: Avanir Pharma

Biotech Stock Mailbag: Avanir Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

The Top FDA Drug Approval Pickers

The Top FDA Drug Approval Pickers

Meet the three winners of TheStreet's FDA Drug Approval Contest.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct 15, 2010.

Update: Perfect FDA Drug Approval Pickers

Update: Perfect FDA Drug Approval Pickers

Meet the five contestants with perfect 5-0 records so far in TheStreet's FDA Drug-Approval Contest

Biotech Winners: King Pharmaceuticals, Pain Therapeutics

Painkillers are in the biotech spotlight Tuesday, as King Pharmaceuticals sells itself to Pfizer and tiny pain medicine developer Pain Therapeutics benefits by extension.

10 Pharmaceutical Stocks With Up to 88% Upside

Analyst sentiment is very strong for most of these highly-rated Big Pharma plays.

Biotech Winners & Losers: Alexza, Geron

Biotech Winners & Losers: Alexza, Geron

Alexza shares crash Monday after the FDA denies approval of a key drug, but Geron gains as the company begins a historic stem-cell study.

"Spend Shift", Action Alerts Plus, Solar Stock Plays

"Spend Shift", Action Alerts Plus, Solar Stock Plays

Guests include Michael D'Antonio, author "Spend Shift", Joseph Berwind, author of "Investing in Solar Stocks", Stephanie Link, director of research Action Alerts Plus

FDA O-Fer October Drug Approvals

U.S. regulators have issued four drug approval decisions this month and all have been rejections.

Alexza Pharm: FDA Doesn't Approve AZ-004

Alexza Pharm: FDA Doesn't Approve AZ-004

FDA refuses to approve Alexza's drug-device AZ-004 for schizophrenia, citing lung safety concerns.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct. 8, 2010.

Readers Pick Drug Approval Winners & Losers

FDA will approve drugs by Alkermes and Amylin but will turn away Arena and Vivus, according to reader predictions in TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

Try to correctly predict the approval decisions made by the U.S. Food and Drug Administration on 11 new drugs in October.

Biotech Calendar: Key Dates for October

Here's a list of October's potentially stock-moving biotech events.

13 Drugs Facing FDA Approval Decisions

Here is the updated list of drugs facing FDA approval decisions.